HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Protara Therapeutics (NASDAQ:TARA) and maintained a $23 price target.
March 14, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Protara Therapeutics and maintained a $23 price target.
The reiteration of a Buy rating and maintenance of a $23 price target by a reputable analyst could positively influence investor sentiment and potentially lead to an increase in the stock price of Protara Therapeutics in the short term. The confidence in this analysis is high due to the direct mention and specific recommendation by the analyst.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100